HUT62900A - Process for producing bicyclic rapamycins - Google Patents

Process for producing bicyclic rapamycins

Info

Publication number
HUT62900A
HUT62900A HU9201781A HU9201781A HUT62900A HU T62900 A HUT62900 A HU T62900A HU 9201781 A HU9201781 A HU 9201781A HU 9201781 A HU9201781 A HU 9201781A HU T62900 A HUT62900 A HU T62900A
Authority
HU
Hungary
Prior art keywords
producing bicyclic
bicyclic rapamycins
rapamycins
producing
bicyclic
Prior art date
Application number
HU9201781A
Other languages
English (en)
Other versions
HU9201781D0 (en
Inventor
Wenling Kao
Robert Lewis Vogel
John Henry Musser
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of HU9201781D0 publication Critical patent/HU9201781D0/hu
Publication of HUT62900A publication Critical patent/HUT62900A/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU9201781A 1991-05-29 1992-05-28 Process for producing bicyclic rapamycins HUT62900A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/706,811 US5120725A (en) 1991-05-29 1991-05-29 Bicyclic rapamycins

Publications (2)

Publication Number Publication Date
HU9201781D0 HU9201781D0 (en) 1992-08-28
HUT62900A true HUT62900A (en) 1993-06-28

Family

ID=24839145

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9201781A HUT62900A (en) 1991-05-29 1992-05-28 Process for producing bicyclic rapamycins

Country Status (9)

Country Link
US (1) US5120725A (hu)
JP (1) JPH05163280A (hu)
KR (1) KR920021555A (hu)
CA (1) CA2069469A1 (hu)
CZ (1) CZ157192A3 (hu)
FI (1) FI922431A (hu)
HU (1) HUT62900A (hu)
MX (1) MX9202545A (hu)
NO (1) NO922112L (hu)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
WO1994015605A1 (en) * 1993-01-14 1994-07-21 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
US5310903A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
US5310901A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives
DE4342672A1 (de) * 1993-12-15 1995-06-22 Akzo Nobel Nv Haftverbesserer
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US20060198867A1 (en) * 1997-09-25 2006-09-07 Abbott Laboratories, Inc. Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US8394398B2 (en) * 1997-09-26 2013-03-12 Abbott Laboratories Methods of administering rapamycin analogs with anti-inflammatories using medical devices
US7357942B2 (en) * 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US8257725B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US8057816B2 (en) * 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
US7378105B2 (en) * 1997-09-26 2008-05-27 Abbott Laboratories Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
US8257726B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
US20060240070A1 (en) * 1998-09-24 2006-10-26 Cromack Keith R Delivery of highly lipophilic agents via medical devices
US7960405B2 (en) * 1998-09-24 2011-06-14 Abbott Laboratories Compounds and methods for treatment and prevention of diseases
US7455853B2 (en) * 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
US8257724B2 (en) * 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US6790228B2 (en) * 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
US20080145402A1 (en) * 2001-09-10 2008-06-19 Abbott Cardiovascular Systems Inc. Medical Devices Containing Rapamycin Analogs
KR101012605B1 (ko) 2002-09-06 2011-02-10 아보트 러보러터리즈 수화 억제제를 포함하는 의료용 장치
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
CA2539324A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
EP1735042B1 (en) * 2004-03-19 2011-11-23 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
US20100030183A1 (en) * 2004-03-19 2010-02-04 Toner John L Method of treating vascular disease at a bifurcated vessel using a coated balloon
US8431145B2 (en) 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
WO2006080951A2 (en) * 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
US8021849B2 (en) * 2004-11-05 2011-09-20 Siemens Healthcare Diagnostics Inc. Methods and kits for the determination of sirolimus in a sample
US8637070B2 (en) 2005-02-09 2014-01-28 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
WO2006102378A2 (en) * 2005-03-21 2006-09-28 Macusight, Inc. Drug delivery systems for treatment of diseases or conditions
EP1868663B1 (en) * 2005-03-23 2011-11-16 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
WO2007032777A2 (en) 2005-03-23 2007-03-22 Abbott Laboratories Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
US7189582B2 (en) * 2005-04-27 2007-03-13 Dade Behring Inc. Compositions and methods for detection of sirolimus
EP2218442A1 (en) 2005-11-09 2010-08-18 CombinatoRx, Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
US7700614B2 (en) 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
EP2001438A2 (en) * 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
US7622477B2 (en) * 2006-02-28 2009-11-24 Cordis Corporation Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
US20070203169A1 (en) * 2006-02-28 2007-08-30 Zhao Jonathon Z Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same
US7678901B2 (en) 2006-02-28 2010-03-16 Wyeth Rapamycin analogs containing an antioxidant moiety
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
CA2664697A1 (en) 2006-09-28 2008-04-10 Follica, Inc. Methods, kits, and compositions for generating new hair follicles and growing hair
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
US20100151436A1 (en) * 2007-03-02 2010-06-17 Fong Peter M Methods for Ex Vivo Administration of Drugs to Grafts Using Polymeric Nanoparticles
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
ES2559311T3 (es) 2007-12-19 2016-02-11 Abbott Laboratories Reactivo de extracción de fármacos inmunosupresores para inmunoanálisis
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
PT2365802T (pt) 2008-11-11 2017-11-14 Univ Texas Microcápsulas de rapamicina e utilização para o tratamento de cancro
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
US8480620B2 (en) * 2009-12-11 2013-07-09 Abbott Cardiovascular Systems Inc. Coatings with tunable solubility profile for drug-coated balloon
US20110144577A1 (en) * 2009-12-11 2011-06-16 John Stankus Hydrophilic coatings with tunable composition for drug coated balloon
US8951595B2 (en) * 2009-12-11 2015-02-10 Abbott Cardiovascular Systems Inc. Coatings with tunable molecular architecture for drug-coated balloon
KR101620661B1 (ko) 2010-04-27 2016-05-12 로슈 글리카트 아게 어푸코실화된 CD20 항체와 mTOR 억제제의 복합 요법
KR101253399B1 (ko) 2010-10-26 2013-04-11 영남대학교 산학협력단 아포지단백질 a-i 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형
AU2012229236B2 (en) 2011-03-11 2017-05-18 Beth Israel Deaconess Medical Center, Inc. Anti-CD40 antibodies and uses thereof
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013163176A1 (en) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
US9408884B2 (en) 2012-06-08 2016-08-09 Biotronik Ag Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods
US20150290176A1 (en) 2012-10-12 2015-10-15 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
EP3760223A1 (en) 2013-04-03 2021-01-06 N-Fold Llc Nanoparticle composition for desensitizing a subject to peanut allergens
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
EP3089737B1 (en) 2013-12-31 2021-11-03 Rapamycin Holdings, LLC Oral rapamycin nanoparticle preparations and use
AU2015237200A1 (en) 2014-03-27 2016-10-06 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
CA2968049A1 (en) 2014-04-16 2015-10-22 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
CA2950589A1 (en) 2014-06-02 2015-12-10 Children's Medical Center Corporation Methods and compositions for immunomodulation
AU2016315873B2 (en) 2015-09-04 2022-08-18 Primatope Therapeutics Inc. Humanized anti-CD40 antibodies and uses thereof
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
BR112018077259A2 (pt) 2016-06-30 2019-06-18 Durect Corporation formulações depot
EA201990127A1 (ru) 2016-12-30 2020-08-18 Дьюрект Корпорейшн Депо-препарат
EP3624863B1 (en) 2017-05-15 2021-04-14 C.R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
JP7262581B2 (ja) 2018-11-14 2023-04-21 ルトニックス,インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
CN113939324A (zh) 2019-04-08 2022-01-14 巴德外周血管股份有限公司 在经改性装置表面上具有药物洗脱涂层的医疗装置
EP4370160A1 (en) 2021-07-15 2024-05-22 President And Fellows Of Harvard College Compositions and methods relating to cells with adhered particles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation

Also Published As

Publication number Publication date
FI922431A (fi) 1992-11-30
CZ157192A3 (en) 1994-01-19
US5120725A (en) 1992-06-09
MX9202545A (es) 1992-11-01
NO922112D0 (no) 1992-05-27
HU9201781D0 (en) 1992-08-28
NO922112L (no) 1992-11-30
CA2069469A1 (en) 1992-11-30
KR920021555A (ko) 1992-12-18
FI922431A0 (fi) 1992-05-27
JPH05163280A (ja) 1993-06-29

Similar Documents

Publication Publication Date Title
HUT62900A (en) Process for producing bicyclic rapamycins
HU911663D0 (en) Process for producing bicyclic 1-aza-cycloalkanes
HUT62904A (en) Process for producing rapamycin dimers
HUT63199A (en) Process for producing l-treonin
HUT70895A (en) Process for producing alfa-alumina
HUT61600A (en) Process for producing l-triptophane
HUT65328A (en) Process for producing bradykinin antagonists
HUT62898A (en) Process for producing pyrazolo- and triazolotriazine compounds
HUT56825A (en) Process for producing substituted 2-chloropyridines
HUT59695A (en) Process for producing hydroxy-ethyl-amine- and norstai
EP0482908A3 (en) Process for producing streptovaricin
HUT58785A (en) Process for producing hypoallergene moth-oils
HU9403434D0 (en) Process for producing imidazopyridine derivatives
HUT58699A (en) Process for producing 2-chloro-5-methyl-pyridine
HU910578D0 (en) Process for producing 4-hydroxiphenethyl-alcohol
HUT61530A (en) Process for producing 1-hydroxyalkyl-5-nitroimidazoles
HUT60239A (en) Process for producing glian
HU910745D0 (en) Process for producing 1-treonine
EP0543633A3 (en) Process for producing 4-amino-3-fluorobenzotrifluoride
SG49204A1 (en) Process for producing alkadienols
HU9402303D0 (en) Improved process for producing 3-carbonyl-androstadiene-17-carboxamides
GB2267705B (en) Process for producing 2-alkyl-4-halo-5-formylimidazoles
HUT64029A (en) Process for producing 2-aminometnhylpyridine
HUT65540A (en) Process for producing bicyclic amidino-hydrazons
HU911601D0 (en) Process for producing phenyl-piperazines

Legal Events

Date Code Title Description
DFC9 Refusal of application